迈阿密大学的研究确定了用于耐药 CLL 患者的下一代 BTK 降解剂化合物，该研究发表在《科学》杂志上。 Study at University of Miami identifies next-gen BTK degrader compound for resistant CLL patients, published in Science.
西尔维斯特综合癌症中心的研究人员发现了下一代 BTK 降解剂 NX-2127，它可以帮助克服慢性淋巴细胞白血病 (CLL) 和相关血癌的治疗耐药性。 Researchers at the Sylvester Comprehensive Cancer Center have discovered a next-generation BTK degrader, NX-2127, which could help overcome treatment resistance in chronic lymphocytic leukemia (CLL) and related blood cancers. 该化合物有效地破坏了培养皿和患者细胞中的细胞靶标，参与该研究的 14 名 CLL 患者中，有 11 名患者的肿瘤缩小了。 The compound effectively destroyed its cellular targets in both petri dishes and patient cells, shrinking tumors in 11 of 14 CLL patients participating in the study. 这可以为肿瘤产生耐药性或对一线治疗无反应的患者提供一种治疗选择。 This could offer a therapeutic option for patients whose tumors become drug-resistant or are unresponsive to frontline treatment.